Glumetinib features good oral absorption and stable metabolism in vivo, and it can easily penetrate the blood-brain barrier, making it suitable for patients with brain metastases.
Authentic
Guarantee
Fast Delivery
Privacy Glumetinib, a MET inhibitor indicated for the treatment of patients with specific non-small cell lung cancer, requires dosage adjustments based on the···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 77
Glumetinib is an oral targeted therapy agent indicated primarily for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harbor···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 79
Glumetinib, a MET inhibitor, is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) harboring MET gene abnormalities.···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 75
Gumetinib is an oral small-molecule MET inhibitor, primarily indicated for the treatment of adult patients with locally advanced or metastatic non-sma···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 82
Savolitinib is a protein kinase inhibitor. It exerts dual therapeutic effects by precisely inhibiting the activity of c-Met protein kinase, a key &quo···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 77
The storage temperature of Gumetinib is generally required to be controlled within a 2°C to 8°C refrigerated environment. It should be stored away fro···【Read More】
Update: 26 Jan,2026Source: Haiou HealthViews: 77
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



